E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Safety and tolerability of Montelukast treatment in Parkinson's disease. |
|
E.2.2 | Secondary objectives of the trial |
To study the anti-inflammatory properties of Montelukast in the brain. To study the inflammatory response in Parkinson’s disease by measuring biomarkers in cerebrospinal fluid, urine and blood. To study pharmacokinetic properties of Montelukast by measuring levels of Montelukast in cerebrospinal fluid and serum. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Diagnosis of clinically probable Parkinson’s disease according to the MDS clinical diagnostic criteria for PD(1) • Males or Females. • Hoehn and Yahr stage ≤ 2 in the ON medication state. This implies that all patients will be mobile without assistance during their best “ON” medication periods. • All patients will be ≥35 and ≤80 years of age. • Signed informed consent to participate in the trial. • High- and mixed affinity binder on TSPO rs6971 polymorphism gene sequencing
|
|
E.4 | Principal exclusion criteria |
• Extended treatment adjustment or significant motor fluctuations during the last 30 days. • Atypical or other causes of parkinsonism. Patients with suspected Multiple System Atrophy, Progressive Supranuclear Palsy, drug-induced parkinsonism, vascular parkinsonism, dystonic or essential tremor will not be included in the trial. • Prior intra-cerebral surgical intervention for Parkinson’s disease. Patients who have previously undergone Deep Brain Stimulation, intra-cerebral administration of growth factors, gene therapy or cell therapies will not be eligible. • Already actively participating in a trial of a device, drug or surgical treatment for Parkinson’s disease. • Previous exposure to Montelukast of more than six months during the last 12 months and not in the last month before entering the trial. • Known abnormality on CT or MRI brain imaging considered likely to compromise compliance with trial protocol/FDG-PET acquisition. • Congenital or acquired abnormal lumbar anatomy which might affect safety and comfort during lumbar puncture procedure. • Co-morbidity with severe heart/lung disease (including asthma), liver disease, dementia, depression or autoimmune disease • Known hypersensitivity to Montelukast or any of the inactive ingredients. • Pregnancy
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Documentation and evaluation of adverse events. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
at 4 and 12 week clinic visits and 2, 6 and 9 week telephone follow up. |
|
E.5.2 | Secondary end point(s) |
1. TSPO expression as measured by [11C]PBR28 PET 2. MDS-UPDRS and NMSquest scores 3. Concentration of Montelukast in CSF, plasma and urine 4. Levels of inflammatory and neurodegeneration biomarkers in plasma and CSF |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Baseline and 12 weeks 2. Baseline, 4 and 12 weeks 3. Baseline and 4 weeks 4. Baseline, 4 and 12 weeks |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | |